Table 4.
Multivariable Cox regression analysis of recurrence and OS between patients with high- or low-risk MVI undergoing AR and LT
| Variable | High-risk MVI |
Low-risk MVI |
||||||
|---|---|---|---|---|---|---|---|---|
| Recurrence |
OS |
Recurrence |
OS |
|||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Before PSM | ||||||||
| HBV-DNA level, ≥2,000 vs <2,000 IU/mL | 2.10 (1.27–3.65) | 0.002 | 2.45 (1.21–4.97) | 0.013 | 1.97 (1.37–2.87) | <0.001 | 2.22 (1.40–3.52) | 0.001 |
| ALB, ≥3.5 vs <3.5 g/dL | – | – | – | – | 0.40 (0.19–0.81) | 0.012 | 0.34 (0.15–0.77) | 0.011 |
| Child–Pugh grade, B7 vs A | 2.09 (1.07–4.08) | 0.031 | ||||||
| Tumor number (I)a, multiple vs solitary | – | – | – | – | 2.02 (1.25–3.27) | 0.004 | 2.16 (1.22–3.84) | 0.008 |
| Tumor capsule (I), incomplete vs complete | – | – | – | – | 2.09 (1.07–4.08) | <0.001 | 2.31 (1.42–3.77) | 0.001 |
| Type of treatment, LT vs AR | 0.23 (0.11–0.46) | <0.001 | 0.11 (0.04–0.34) | <0.001 | – | – | – | – |
| After PSM | ||||||||
| HBV-DNA level, ≥2,000 vs <2,000 IU/mL | 1.94 (1.02–3.68) | 0.041 | 3.63 (1.38–9.55) | 0.009 | 2.28 (1.33–3.90) | 0.003 | 2.60 (1.35–5.01) | 0.004 |
| Tumor number (I)a, multiple vs solitary | 2.58 (1.38–4.82) | 0.003 | – | – | 3.08 (1.62–5.88) | 0.001 | 3.29 (1.50–7.19) | 0.003 |
| Tumor capsule (I), incomplete vs complete | – | – | – | – | 2.60 (1.47–4.58) | 0.001 | 3.33 (1.65–6.71) | 0.001 |
| Type of treatment, LT vs AR | 0.24 (0.11–0.53) | <0.001 | 0.17 (0.06–0.52) | 0.002 | – | – | – | – |
OS, overall survival; MVI, microvascular invasion; PSM, propensity score matching; HBV-DNA, hepatitis B virus-deoxyribonucleic acid; LT, liver transplantation; AR, anatomical resection; HR, hazard ratio; CI, confidence interval.
a
(I) was based on preoperative imaging studies.